Despite continuous advances in the knowledge of the biology of acute myeloid leukemia (AML), the prognosis of AML patients treated with standard chemotherapy is still poor, especially in the elderly (> 60 y). It should be considered that AML mainly develops in the elderly, with a median age at diagnosis of 68 y and a growing incidence over 65 y. AML accounts for about 25% of all adult leukemias...

Mixed phenotype acute leukemia (MPAL) is a complex entity expressing both lymphoid and myeloid immunophenotyping. In the present study, 47 MPAL, 60 lymphoid antigen-positive acute myeloid leukemia (Ly(+)AML), and 90 acute myeloid leukemia with common myeloid immunophenotype (Ly(-)AML) patients were investigated. We found that, in MPAL patients, there were high proportions of blast cells in bone...

Abstract Background It has been postulated that the interaction between environmental risk factors and genetic susceptibility is a possible cause for development of acute myeloid leukemia (AML). Cytochrome P450 (CYP) detoxification enzymes are responsible elimination oxidative stress. Genetic polymorphisms in these may AML due to enhanced accumulation reactive oxygen species. To study associati...

BACKGROUND Leukemia stem cells (LSC) are involved in the incidence, drug resistance, and relapse of leukemia while LSC-related antigen CD33, CD96, and DAPK expression in AML and its prognosis is still unclear. This study explored LSC-related antigens expression in acute myeloid leukemia (AML) and its prognosis. MATERIAL AND METHODS A total of 156 cases of AML patients were enrolled in the exper...

background: acute myeloid leukemia (aml) is an immunophenotypically heterogeneous malignant disease, in which cd34 positivity is associated with poor prognosis. osteopontin (opn) plays different roles in physiologic and pathologic conditions like: survival, metastasis and cell protection from cytotoxic and apoptotic stimuli. due to anti-apoptotic effect of opn in normal and malignant cells, sil...

BACKGROUND Clofarabine is a second-generation nucleoside analogue. The aim of the study was the analysis of ex vivo activity of clofarabine and 14 other anticancer drugs in pediatric and adult acute lymphoblastic (ALL) and myeloid (AML) leukemia. PATIENTS AND METHODS The ex vivo drug resistance profile was analyzed in 282 patients, including 201 children with ALL de novo, 24 children with rel...

The prognosis of relapsed acute myeloid leukemia (AML) in elderly patients is dismal, even if the AML exhibits a good prognostic karyotype, such as inv(16)(p13.1q22). We present a 72-year-old female with AML with inv(16)(p13.1q22) who suffered five episodes of relapse with temporary complete remission. Maintenance chemotherapy with oral cytarabine ocfosfate hydrate eventually produced persisten...

Trisomy 10 as the sole cytogenetic abnormality in AML is rare, with an incidence rate of < 0.5%. It tends to affect the elderly and is extremely rare in pediatric patients. We describe a case of an 8-month-old Caucasian baby who presented with prominence of left eye and fever without lymphadenopathy or hepatosplenomegaly. Bone survey showed diffuse periosteal reaction in the femur, pelvis, maxi...

INTRODUCTION The incidence of common fusion transcripts in AML is 40-45%, but data from Indian sub-continent is limited. AIMS #ENTITYSTARTX00026; OBJECTIVES The aim of the present study is to note the incidence of common fusion transcripts of AML1-ETO, PML-RARA and CBFβ-MYH11 in adult and pediatric AML cases. MATERIALS #ENTITYSTARTX00026; METHODS A total of 116 AML cases diagnosed on bone...

Two recent reports by Ramanathan et al. and Hansford et al. commented on the findings of our paper “Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study” in which we evaluated the clinical features and the efficacy of treatments in 43 patients at onset of a leukemic form of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since there is no c...